Schedule 13G ownership disclosure

Fennec Pharmaceuticals Inc

Common stock, no par value (the "Shares") · CUSIP: 31447P100

Event date: 2025-12-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Sonic Fund II, L.P.

    Shares: 2,607,357 · Class: 7.6%

  • Sonic GP LLC

    Shares: 2,607,357 · Class: 7.6%

  • Kam Lawrence

    Shares: 2,799,959 · Class: 8.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001013594-26-000251
Form type
SCHEDULE 13G/A
Filer
FENNEC PHARMACEUTICALS INC.
CIK
CIK 1211583
Filed
Feb 17, 2026
Reporting period
Dec 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub